Counterpoint: the case for immediate active treatment.
Active monitoring strategies recently have received attention as possible treatment options for men with low-risk prostate cancer who have a life expectancy of more than 10 years. However, no current criteria sufficiently predict outcomes for individuals with clinically localized disease and an otherwise long life expectancy who undergo either immediate or delayed treatment, or no treatment. This article describes the available evidence regarding treatment outcomes in men with low-risk prostate cancer and presents the case for immediate active treatment.
Loeb
Stacy
S
Department of Urology, Georgetown University School of Medicine, Washington, DC, USA.
Catalona
William J
WJ
D006801:Humans; D008017:Life Expectancy; D008297:Male; D011159:Population Surveillance; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*